An observational study in Coronary Artery Disease, sponsored by Duk-Woo Park, MD. Recruiting at 11 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Duk-Woo Park, MD · Observational
This study is to evaluate the effectiveness and safety of Ultimaster Tansei stent and/or Ultimaster Nagomi stent in the "real-world" daily practice.
4,857 studies on the registry are indexed under Coronary Artery Disease; 890 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 320 across 1,687 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Duk-Woo Park, MD is the lead sponsor of 15 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with Ultimaster™ Tansei™ stent and/or Ultimaster Nagomi™ stents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with coronary artery disease
Device: Ultimaster™ Tansei™ stent and/or Ultimaster Nagomi™ stent
Patients receiving Ultimaster™ Tansei™ stent and/or Ultimaster Nagomi™ stent
The composite event rate of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)
the composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR) at 12 months post-procedure. A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event that is considered to have occurred if any one of several different events is observed.
Time frame: 1 year
The event rate of all death
Time frame: 5 years
The event rate of cardiac death
Time frame: 5 years
The event rate of myocardial infarction
Time frame: 5 years
The composite event rate of death or myocardial infarction
Time frame: 5 years
the composite event rate of cardiac death or myocardial infarction
Time frame: 5 years
The event rate of target-vessel revascularization
Time frame: 5 years
The event rate of target-lesion revascularization
Time frame: 5 years
The event rate of stent thrombosis
According to Academic Research Consortium(ARC) criteria
Time frame: 5 years
The event rate of stroke
Time frame: 5 years
The event rate of procedural success
Defined as achievement of a final diameter stenosis of \<30% by visual estimation, without the occurrence of death, Q-wave MI, or urgent revascularization during the index hospitalization.
Time frame: 3 days
The event rate of bleeding complications
TIMI(Thrombolysis in Myocardial Infarction), BARC(Bleeding Academic Research Consortium) criteria
Time frame: 5 years
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Duk-Woo Park, MD